Classical gene amplifications in human breast cancer are not associated with distant solid metastases. by Driouch, K. et al.
British Journal ofCancer (1997) 76(6), 784-787
© 1997 Cancer Research Campaign
Classical gene amplifications in human breast cancer
are not associated with distant solid metastases
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Summary To determine the relationship between breast cancer progression and gene amplification, we screened 62 distant metastases and
122 primary breast tumours for the amplification of the proto-oncogenes MYC and ERBB2and the 11ql3 chromosomal region. Surprisingly,
solid metastases showed an absence of gene amplification. These results suggest that the amplification of the proto-oncogenes MYC and
ERBB2and the 11ql3 chromosomal region seem to be involved mainly in the genesis ofthe primary breast tumour ratherthan its progression.
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Breast cancer is the most common malignancy in women; one in
nine Caucasian women are likely to develop breast cancer in their
lifetime. Cancer progression can be divided into two major
processes: primary site tumorigenesis and metastasis. Metastases
are the main cause of death from cancer. Both genetic and epi-
genetic events may be involved in the process by which individual
cells acquire the characteristics required for invasion, dissemina-
tion, survival and growth at the metastatic site. Cells have a genet-
ically determined metastatic potential (Liotta et al, 1991). While
tumorigenesis is known to involve multiple genetic alterations
(Bishop, 1991), the situation is probably far more complex in the
case ofmetastases.
Breast cancer results from early and/or late mutational events.
Constitutional mutations in susceptibility genes (BRCAI, BRCA2,
TP53, etc.) confer a predisposition to familial breast cancer.
Sporadic breast cancer occurs through an accumulation ofsomatic
mutations, i.e. amplifications of proto-oncogenes (MYC and
ERBB2) and chromosomal band 1 q13, mutations of TP53 and
loss of heterozygosity (LOH) of chromosomes and chromosome
arms 1, 3p, 6q, 7q, 8p, 11, 13q, 16q, 17, 18q and 22q (Bieche and
Lidereau, 1995).
If alterations of specific genes are associated with the invasive
process, they would probably be more frequently altered in metas-
tases than in primary tumours. Brison (1993) reviewed several
studies on different primary human tumours at different stages and
suggested that proto-oncogene amplifications are probably late
events in tumour progression. However, it is not yet known
whether specific chromosomal regions are involved in invasive
breast carcinoma because ofa lack ofscreening studies for genetic
alterations in secondary events, in particular distant metastases.
MATERIALS AND METHODS
Here we investigated the role of genetic amplifications in the
acquisition of metastatic potential by means of restriction
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fragment length polymorphism (RFLP) analysis of 62 distant
metastases and 122 primary breast tumours at chromosomal loci
that are frequently amplified (MYC, ERBB2, IN72/FGF3 and
CCNDI) in primary breast cancer. Local recurrences were
excluded from the study because they are not considered to result
from dissemination; they can be due to residual cancer cells after
inadequate surgery (Veronesi et al, 1995).
The metastases (18 solid samples and 44 pleural effusions) were
obtained from patients at Marseille Nord Hospital (Marseille),
Bicetre Hospital (Paris) and the Centre Rene Huguenin (St-Cloud),
while all 122 excised primary breast tumour samples were
collected from patients treated at the Centre Rene Huguenin. The
primary tumours (2 cm or greater) were classified according to the
World Health Organization Histological Typing ofBreastTumours
(Scraff and Torloni, 1981). The tumours were mostly invasive
(85%); 40% ofthem were grade II and40% were grade III. A third
of the tumours did not show any lymph node metastases (N-).
Primary tumours and matching pleural effusions were available
from 12 patients. None ofthe 122 patients had undergone radiation
therapy or chemotherapy before primary surgery. Patients whose
metastases were sampled had undergone different adjuvant thera-
pies. The median time to diagnosis of the distant metastases after
primary breast surgery was 6 years (range 1-17 years).
Samples were stored in liquid nitrogen immediately after
surgery. DNA was extracted from tumour tissue and peripheral
lymphocytes using standard methods (Maniatis et al, 1982). Ten
micrograms of DNA from each sample was digested with the
appropriate restriction endonuclease and examined by Southern
blotting. Oncogene amplification was detected with the pRyc 7.4
probe for the MYCproto-oncogene mapped on 8q24 (Rushdi et al,
1983) and the pMAC 117 probe for the ERBB2 gene located on
17ql1.2-ql2 (no. 53408; American Type Culture Collection,
Rockville, MD, USA). The SS6 probe (Casey et al, 1986) and the
pPL-8 probe (Motokura et al, 1991) were used to test for
INT2IFGF3 and CCNDI gene amplifications on 1lql3 chromo-
somal band respectively. The control probes corresponded to the
HBB gene (American Type Culture Collection no. 39698) and the
proto-oncogene MOS (American Type Culture Collection no.
41004). Gene amplification analyses were performed as previ-
ously described (Escot et al, 1986).
784Gene amplifications in distantmetastases ofbreastcancer 785
Table 1 Incidence of gene amplifications in distant metastases and primary
tumours of human breast cancer
Locus Chromosome Primary Distant PLvaluea
symbol location tumours metastases
(%) (%)
MYC 8q24 22.9 (28/122)b 8.1 (5/62) < 0.05
INT2/FGF3-CCND1 11q13 21.3 (26/122) 16 (8/50) NS
ERBB2 17q11.2-q12 20.5 (25/122) 9.8 (5/51) NS
aFisher's exact test. bCases with gene amplification/cases tested.
Table 2 Frequency of gene amplifications in subgroups of breast cancer
metastases
Locus Solid Pleural PLvalue
symbol metastases effusions
(%) (%)
MYC 5.6 (1/18)b 9.1 (4/M) NS
INT2/FGF3-CCND1 0 (0/18) 25 (8/32) < 0.05
ERBB2 5.9 (1/17) 11.8 (4/34) NS
aFisher's exact test. bCases with gene amplification/cases tested.
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Figure 1 Southern hybridization of three matched DNAs from human
primary breast tumours (T), pleural effusions (E) and peripheral leucocytes
(L). Case 301 showed gene amplifications on the FGF3and ERBB2 genes in
the metastatic sample but not in the primary tumour. In contrast, gene
amplifications were observed in the primary tumours but not in the pleural
effusions in cases 515 and 1156 on the ERBB2and MYCloci respectively.
The MOSprobe was used as a control for DNA amount
RESULTS
The degree of amplification on the four markers, quantified by
means of densitometry, varied from two- to 20-fold in both
primary tumours and distant metastases. Gene amplifications in
the distant metastases and primary tumours are summarized in
Table 1. This series of primary breast tumours (122 samples) had
previously been analysedby ourgroup (Bieche et al, 1994) and the
frequencies of gene amplifications were in accordance with those
reported elsewhere (Adnane et al, 1989; Garcia et al, 1989; Berns
et al, 1992).
Surprisingly, in the series of metastatic samples, the frequency
ofMYC gene amplification was significantly lower (Fisher's exact
test) in distant metastases than in primary tumours (5 out of 62 vs
28 out of 122; P < 0.05). ERBB2 gene amplification also tended to
be less frequent in the metastases, although the difference was not
statistically significant. The frequency of amplification of the
11q13 band was similar in primary tumours and metastases.
To investigate possible links between gene amplification and
the type of metastasis, we subdivided the metastatic specimens
into 18 solid metastases (lung, nodes, skin, liver and muscle) and
44 pleural effusions (Table 2). The frequencies ofgene amplifica-
tion were far lower in the solid metastases. Only 2 out of 18 (11%)
solid metastases showed amplifications on at least one ofthe four
genes tested (MYC in one case and ERBB2 in the other). This
frequency was 32% (14 out of 44) in pleural effusions and 51%
(62 out of 122) in primary tumours. While MYC and ERBB2 gene
amplifications were less frequent in pleural effusions than in
primary tumours, the frequency of llql3 amplification was
similar to that of primary tumours and higher than in the solid
metastases (P < 0.05).
The absence of gene amplifications in the solid metastases was
not due to masking by a large proportion ofcontaminating normal
cells. In a previous study of the same DNA samples, we found
high frequencies of LOH on 7q31 (MET locus) and llpl5.5
(HRAS locus) in this series of metastatic samples, suggesting a
relatively high proportion of tumour cells (Champeme et al,
1995a). These results support the hypothesis that different molec-
ular processes are involved in different secondary events.
The results of the analysis of 12 pairs of primary tumours and
pleural effusions are reported in Table 3 and Figure 1. In most
cases, gene amplifications were observed in either the primary
tumour or the metastasis on theMYC locus (four cases), the 11q13
band (two cases) or the ERBB2 gene (three cases). Only one case
had a gene amplification in the primary tumour and its matching
metastasis, on chromosomal band 11q13. Nevertheless, this genic
amplification did not affect the same allele in the primary tumour
and the pleural effusion. Four pairs ofsamples were not amplified
in any ofthe three chromosomal regions tested.
Table 3 Gene amplifications in 12 paired samples (primary tumours and pleural effusions from the same patient)
Number of altered cases Number of unaltered cases
Locus symbol T only E only T and E T and E
MYC 2 2 0 8
INT2IFGF3-CCND1 1 1 1 9
ERBB2 1 2 0 9
T, primary tumour; E, pleural effusion.
British Journal ofCancer(1997) 76(6), 784-787 0 CancerResearch Campaign 1997786 KDriouch etal
DISCUSSION
In agreement with other studies on primary breast tumours (Bieche
et al, 1994), no link was found between the occurrence ofthe three
gene amplifications within the same distant metastatic samples,
suggesting that the three regions most frequently amplified in
primary breast tumours are also independently affected in
metastatic specimens.
Our data suggest that the three regions of amplification are not
involved in the process by which cells acquire metastatic capacity.
Our findings are in agreement with those of Watson et al (1993),
who suggested that MYC gene amplification can occur at an early
stage of tumour progression and does not always persist in nodal
metastases. Taken together, the results of this latter study and of
our own study suggest that MYC (and also ERBB2) amplification
plays a major role in the development ofprimary breast cancer but
not in the distant spread oftumour cells. The 11q13 region, which
was not amplified in any of the distant solid metastases but was
amplified in pleural effusions with a similar frequency to that in
primary breast tumours, probably contributes to rapid growth of
cancer cells in the pleura as well as in local recurrences, as we
have previously suggested (Champeme et al, 1995b). These results
could be related to the presence of the CCNDI gene (involved in
the cell cycle) in the llql3 region. In the primary tumours, the
predominant cell subclone bearing the gene amplification does not
seem to have the potential to invade, migrate or proliferate at a
secondary site. A minority of cell subclones in primary tumours
would have the capacity to disseminate.
As the patients in this study underwent non-randomized treat-
ments, further investigations are required to determine whether
the distant metastases derived from these cells were favoured by
adjuvant therapies.
Few studies ofgenetic alterations in secondary events ofhuman
breast cancer have been reported; in addition, most data have been
obtained with lymph node metastases present at the time of
primary surgery (Chen et al, 1992; Bonsing et al, 1993). These
studies yielded similar frequencies of genetic alterations in node
metastases and primary breast tumours and pointed to the same
clonal origin. In contrast, we observed a relatively low frequency
of gene amplification in this series of metastatic samples,
including lymph nodes, obtained some years afterprimary surgery.
Lymph node metastases present atthe time ofsurgery couldbe due
to the passive spread ofmalignantcells and may represent the bulk
of tumour cells at the primary site as regards gene amplification,
whereas late distant metastases might require activation or inacti-
vation ofspecific genes.
In conclusion, the less frequent amplification ofcertain genes in
breast cancer metastases than in primary tumours fits with the
concept that tumour progression is a multistep process. The
genetic events required for tumorigenesis and metastatic spread
are probably different, although metastatic potential might be
acquired early during tumour development. Our findings suggest
that amplification of the proto-oncogenes MYC and ERBB2 and
chromosomal region 11q13, known to be responsible for overex-
pression, are involved in the genesis ofprimary breast tumours but
to a lesser degree, or not at all, in the later stages (metastasis
formation). But cases of overexpression without amplification are
also known, therefore MYC, ERBB2 and CCNDJ may be activated
in tumour cells by mechanisms other than amplification (Guerin et
al, 1988; Gillett et al, 1994). Studies of genetic alterations
involved in the acquisition of metastatic potential should be
conducted to identify suppressor genes and oncogenes that could
be specifically altered in particular metastases and could
contribute to growth in this new tissue.
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